Krystal Biotech — Pioneering Redosable Gene Therapy in Dermatology and Beyond

Krystal Biotech, Inc. is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on developing redosable gene therapies for serious rare and prevalent diseases. The company's proprietary platform utilizes engineered herpes simplex virus type 1 (HSV-1) vectors to deliver therapeutic genes to target cells. Unlike traditional gene therapy vectors such as AAV, HSV-1 vectors can be re-administered multiple times without being neutralized by the immune system, enabling chronic redosing where needed.

The company's lead product, VYJUVEK (beremagene geperpavec), was approved by the FDA in May 2023 for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder caused by mutations in the COL7A1 gene, leading to severe skin fragility and blistering. VYJUVEK is a topical gel applied directly to wounds, designed to deliver functional copies of the COL7A1 gene to skin cells, promoting wound healing and closure. It is the first and only approved redosable gene therapy in the world.

Krystal generates revenue primarily through the commercial sale of VYJUVEK. The company's commercial infrastructure includes a specialized sales force targeting dermatologists, wound care centers, and genetic counselors who treat DEB patients. The company also generates interest income on its cash reserves. As of the latest quarter, Krystal has treated over 100 patients with VYJUVEK, with a growing base of recurring users who apply the gel regularly to manage their condition.

The company employs approximately 300 people and operates research, development, and manufacturing capabilities, including its own cGMP manufacturing facility in Pittsburgh. Krystal's pipeline extends beyond DEB into cystic fibrosis (KB407), lamellar ichthyosis (KB105), and aesthetic dermatology (KB301), demonstrating the platform's flexibility across different tissues and routes of administration.

• Near-Term: VYJUVEK Commercial Expansion: Krystal's immediate growth driver is the continued commercial ramp of VYJUVEK. The company estimates there are approximately 3,000 DEB patients in the US, with only a fraction currently on therapy. Management is focused on expanding the number of active treatment centers, improving patient identification through partnerships with patient advocacy groups, and streamlining the reimbursement process. The company has guided to sustained revenue growth as new patients initiate therapy and existing patients continue chronic use.
• Medium-Term: Geographic Expansion: VYJUVEK has received Orphan Drug Designation in Europe and Japan, and the company plans to file for regulatory approvals in these regions over the next 12-18 months. International expansion could add 30-50% to the addressable patient population and provide incremental revenue growth beyond the US market.
• Pipeline Catalysts: KB407 for Cystic Fibrosis: The Phase 1/2 clinical trial for KB407, an inhaled gene therapy for CF, is ongoing. CF affects approximately 30,000 patients in the US, and current CFTR modulator therapies (Vertex's Trikafta) do not work for all patients, particularly those with nonsense mutations. KB407 is designed to deliver a functional CFTR gene to airway epithelial cells, potentially offering a universal treatment regardless of mutation type. Interim data from this trial is expected in late 2026 or early 2027, representing a significant potential catalyst.
• Additional Pipeline Value: KB105 for lamellar ichthyosis (a rare skin disease with ~10,000 US patients) is in Phase 2, and KB301 for aesthetic indications (wrinkle reduction) is in early development. While these are smaller indications, they demonstrate the platform's breadth and could provide additional revenue streams in the medium term.

Note: 2023-2024 figures are actuals; 2025-2027 are analyst estimates. EPS reported in the snapshot ($7.99) reflects non-operating gains, including a one-time fair value adjustment from warrants or other non-cash items.

The company's financial profile is characterized by a transition from heavy investment phase to commercial scaling. Revenue growth of 4x from 2024 to 2026E reflects the continued ramp of VYJUVEK and potential international launches. While the company remains loss-making on a GAAP basis through 2026, operating losses are narrowing as revenue growth outpaces expense growth. The company's high gross margin (95%) reflects the low cost of goods for a topical gel product. Management has guided to profitability by 2027, assuming continued pipeline progress and no major new investments. The balance sheet remains strong with over $500M in cash, providing a runway into 2027 without the need for additional financing.

The gene therapy market is projected to grow from $8.5B in 2024 to over $25B by 2030, driven by approvals in rare diseases and expanding indications. Within this landscape, Krystal occupies a unique niche: redosable, topically-administered gene therapy. Most gene therapies (e.g., Novartis' Zolgensma, BioMarin's Hemgenix) are one-time, systemic treatments for severe diseases, often with multi-million-dollar price tags. Krystal's approach is differentiated by its ability to treat chronic conditions requiring repeated administration, creating a recurring revenue model.

In the DEB space specifically, Krystal has no direct FDA-approved competitors. Other companies in the broader epidermolysis bullosa space include:

• Abeona Therapeutics (ABEO): Developing EB-101, an autologous cell therapy for recessive DEB, which is in Phase 3 trials. EB-101 involves surgical grafting of gene-corrected skin cells, a more invasive approach than VYJUVEK's topical gel.
• Castle Creek Biosciences: Developing a gene-modified cell therapy for recessive DEB. Their approach also involves surgical implantation, limiting scalability compared to Krystal's topical product.
• Fibrocell Science (acquired by Castle Creek): Previously developing autologous fibroblast therapy for EB, but no approved products.

In the broader gene therapy landscape, Krystal's platform competes with traditional AAV-based approaches but offers the key advantage of redosing. For cystic fibrosis, KB407 would compete with Vertex Pharmaceuticals' CFTR modulators (Trikafta, Kaftrio), which are highly effective for ~90% of CF patients with the F508del mutation. KB407 targets the remaining ~10% who cannot benefit from modulators, representing a niche but significant unmet need.

Krystal's competitive moat lies in its proprietary HSV-1 vector platform, which has been optimized for topical and inhaled delivery. The company holds broad intellectual property covering the vector design, manufacturing processes, and method of use for multiple genes and indications. This IP position, combined with first-mover advantage in DEB, creates significant barriers to entry for potential competitors.

Discounted Cash Flow (DCF) Analysis: Our DCF analysis values Krystal at approximately $410 per share, implying a market value of ~$12.1B. Key assumptions include:

• Revenue growth from $160M in 2025E to $1.2B by 2032E, driven by VYJUVEK's ramp (US + international), KB407 approval in CF by 2029-2030, and KB105 approval by 2028.
• Peak revenue for VYJUVEK estimated at $700M (assuming ~1,000 patients at $600K/year with 70% penetration of addressable patients).
• KB407 peak revenue estimated at $400M (assuming 5,000 patients at $80K/year, capturing ~20% of the non-modulator-eligible CF population).
• Operating margin expanding to 35% at peak, consistent with specialty pharma economics.
• Discount rate of 10%, reflecting the company's beta of 0.54 (lower than typical biotech) but with pipeline risk premium.
• Terminal growth rate of 3% beyond 2032.

Comparable Company Analysis:

Krystal trades at a significant premium to its rare disease peers on EV/Sales, reflecting the market's expectation of high growth and pipeline optionality. However, on an absolute basis, the valuation is justified by the platform's breadth and the large addressable market in CF. The stock's beta of 0.54 suggests lower volatility than the market, which supports a relatively low discount rate in our DCF. At the current price of $354.77, the stock trades approximately 13% below our DCF-derived fair value of $410, suggesting modest upside.

• Commercial Execution Risk: VYJUVEK's revenue ramp may disappoint if patient identification proves slower than expected, reimbursement challenges arise, or physician adoption lags. The company's guidance assumes a significant acceleration in new patient starts, which may not materialize if the sales force fails to reach the fragmented DEB patient population.
• Pipeline Failure Risk: KB407's Phase 1/2 trial in cystic fibrosis could fail to demonstrate sufficient efficacy or safety. The inhaled route of administration for gene therapy is unproven, and delivery efficiency to airway epithelial cells may be inadequate to achieve clinical benefit. A negative readout would significantly reduce the company's addressable market and growth narrative.
• Manufacturing and Supply Chain Risk: As a gene therapy product, VYJUVEK's manufacturing process is complex and subject to regulatory oversight. Any scale-up issues, contamination events, or supply disruptions could impact commercial supply and revenue. The company's reliance on a single manufacturing facility amplifies this risk.
• High Short Interest and Volatility: With 17.73% of the float shorted, the stock may experience elevated volatility driven by short-covering rallies or short-seller-driven selloffs. Negative clinical or commercial news could trigger sharp declines given the crowded short interest.
• Competitive Threat from Alternative Technologies: While Krystal has no direct DEB competitor, advances in other gene therapy approaches (e.g., CRISPR-based editing, mRNA therapies) could eventually provide competing treatments. Additionally, if Abeona's EB-101 or Castle Creek's therapy gains approval, they could capture a portion of the DEB market, particularly among patients with more severe disease who may prefer a potentially curative surgical approach.